In July 2016 Phosphagenics and Terumo signed a Joint R&D Agreement to further
optimise the world’s first transparent formulation of propofol, initially developed by
Phosphagenics leveraging its proprietary TPM® technology. Over the past 15 months
the parties have closely collaborated to further the development of this product.
Earlier this year the parties finalised a formulation that has been successfully taken
through a battery of in vitro assays, including 6-month real-time (room temperature)
and accelerated (40°C) stability, indicating the potential for a 2-year shelf life. The
parties have also shown that the TPM®/Propofol formulation is compatible with several
common diluents used during the infusion process.
The collaboration has allowed the parties to generate two separate patent applications,
which will be progressed in all key territories. The first of these is a Phosphagenics
patent intended to protect the use of TPM® in a range of injectable formulations. The
second is a joint Phosphagenics-Terumo patent specifically for the TPM®/Propofol
formulation.
tpgs didn't cut the mustard obviously
sorry bout the messy format..dont know why
- Forums
- ASX - By Stock
- AVE
- Ann: Phosphagenics Update on TPM/Propofol Development Program
Ann: Phosphagenics Update on TPM/Propofol Development Program, page-27
Featured News
Add AVE (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.507M |
Open | High | Low | Value | Volume |
0.3¢ | 0.3¢ | 0.2¢ | $255 | 107.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
63 | 90918113 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 55054085 | 13 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
63 | 90918113 | 0.002 |
22 | 76000009 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 55054085 | 13 |
0.004 | 20035737 | 17 |
0.005 | 19749333 | 10 |
0.006 | 20865067 | 11 |
0.007 | 10865221 | 9 |
Last trade - 15.44pm 22/07/2024 (20 minute delay) ? |
Featured News
AVE (ASX) Chart |